GlaxoSmithKline agrees to disclose Unicef prices
19 May 2011 00:00 in Pharmaceutical Company Financials
GlaxoSmithKline has said it will publish details of how much it charges Unicef for vaccines.
Britain's largest pharmaceutical firm is working with the humanitarian organisation to enable the retrospective disclosure of prices, as well as information about future transactions, the Telegraph reports.
The company is currently one of the largest suppliers to Unicef, providing it with vaccines for illnesses such as meningitis and hepatitis B.
Although the United Nations organisation began publishing cost data agreed with suppliers for a range of products earlier this year, GlaxoSmithKline is one of several firms that did not initially approve the disclosure of its prices.
The company came under pressure from medical charity Medecins sans Frontieres over the policy and has now decided to change its stance.
A spokesperson for GlaxoSmithKline told the newspaper that the move should help stakeholders to make "informed decisions for future vaccine procurement".
Headquartered in New York, Unicef is active in 190 countries and exists to help children whose lives are affected by poverty, violence and disease.
Other news stories from 19/05/2011
Related news
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency
